N R Jog1,2, I Blanco3, I Lee4, C Putterman3, R Caricchio5,6. 1. Rheumatology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 2. Current affiliation: Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA. 3. Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA. 4. Nephrology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 5. Rheumatology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA roc@temple.edu. 6. Department of Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Abstract
INTRODUCTION: High-mobility group box 1 protein (HMGB-1) has been implicated in the pathogenesis of lupus nephritis (LN). There is increased HMGB-1 expression in the kidneys and increased levels are observed in serum and urine of patients with LN. This study was performed to determine whether the increased urinary HMGB-1 was specific for active lupus or secondary to renal damage. METHODS: Urine from 61 lupus patients (32 had active LN and 29 had systemic lupus erythematosus (SLE) with no evidence of LN) and 14 control proteinuric patients (all with hypertension and eight also with diabetes) were included in this study. HMGB-1 was detected by Western blot. Urine protein was normalized to urine creatinine to account for volume of the specimen. RESULTS: Median normalized urine HMGB-1 levels were significantly elevated in LN patients compared to lupus patients without kidney disease (53.81 vs 9.46, p < 0.001). A difference in median levels was seen between LN classes, with a significant difference between proliferative and membranous disease (33.4 vs 138.8, p = 0.003). Urine protein to urine creatinine ratio (P/C) correlated with urinary HMGB-1 (r = 0.52, p < 0.001), but across the classes this was true only for membranous disease (r = 0.71, p = 0.022, proliferative, p = 0.63; mixed, p = 0.34). CONCLUSIONS: HMGB-1 is elevated in the urine of patients with active LN. Levels are associated with LN class, and higher levels of urinary HMGB-1 are seen in patients with class V when compared to both proliferative and mixed classes. Therefore, urinary HMGB-1 may be suggestive of membranous LN and warrants further evaluation in a large lupus cohort.
INTRODUCTION:High-mobility group box 1 protein (HMGB-1) has been implicated in the pathogenesis of lupus nephritis (LN). There is increased HMGB-1 expression in the kidneys and increased levels are observed in serum and urine of patients with LN. This study was performed to determine whether the increased urinary HMGB-1 was specific for active lupus or secondary to renal damage. METHODS: Urine from 61 lupuspatients (32 had active LN and 29 had systemic lupus erythematosus (SLE) with no evidence of LN) and 14 control proteinuric patients (all with hypertension and eight also with diabetes) were included in this study. HMGB-1 was detected by Western blot. Urine protein was normalized to urine creatinine to account for volume of the specimen. RESULTS: Median normalized urine HMGB-1 levels were significantly elevated in LN patients compared to lupuspatients without kidney disease (53.81 vs 9.46, p < 0.001). A difference in median levels was seen between LN classes, with a significant difference between proliferative and membranous disease (33.4 vs 138.8, p = 0.003). Urine protein to urine creatinine ratio (P/C) correlated with urinary HMGB-1 (r = 0.52, p < 0.001), but across the classes this was true only for membranous disease (r = 0.71, p = 0.022, proliferative, p = 0.63; mixed, p = 0.34). CONCLUSIONS:HMGB-1 is elevated in the urine of patients with active LN. Levels are associated with LN class, and higher levels of urinary HMGB-1 are seen in patients with class V when compared to both proliferative and mixed classes. Therefore, urinary HMGB-1 may be suggestive of membranous LN and warrants further evaluation in a large lupus cohort.
Authors: Dániel Érces; Miklós Nógrády; Enikő Nagy; Gabriella Varga; Andrea Vass; Gábor Süveges; Masaki Imai; Noriko Okada; Hidechika Okada; Mihály Boros; József Kaszaki Journal: Crit Care Med Date: 2013-11 Impact factor: 7.598
Authors: Xiaoping Qing; Milena Pitashny; David B Thomas; Franck J Barrat; Mark P Hogarth; Chaim Putterman Journal: Immunol Lett Date: 2008-09-24 Impact factor: 3.685
Authors: Miriam C Banas; Bernhard Banas; Kelly L Hudkins; Tomasz A Wietecha; Masayuki Iyoda; Elisabeth Bock; Peter Hauser; Jeffrey W Pippin; Stuart J Shankland; Kelly D Smith; Benjamin Stoelcker; Gang Liu; Hermann-Josef Gröne; Bernhard K Krämer; Charles E Alpers Journal: J Am Soc Nephrol Date: 2008-02-06 Impact factor: 10.121
Authors: Deena A Abdulahad; Johanna Westra; Johannes Bijzet; Sebastian Dolff; Marcory C van Dijk; Pieter C Limburg; Cees G M Kallenberg; Marc Bijl Journal: Arthritis Res Ther Date: 2012-08-14 Impact factor: 5.156
Authors: Ryan J Pachucki; Chelsea Corradetti; Lynne Kohler; Jay Ghadiali; Paul M Gallo; Lauren Nicastro; Sarah A Tursi; Stefania Gallucci; Çagla Tükel; Roberto Caricchio Journal: Arthritis Rheumatol Date: 2020-10-11 Impact factor: 10.995
Authors: C S Syahidatulamali; W G Wan Syamimee; Y Nor Azwany; K K Wong; C H Che Maraina Journal: J Postgrad Med Date: 2017 Oct-Dec Impact factor: 1.476